Login to Your Account

Top-Line Results for Genentech/ Immunogen's T-DM1 No Surprise

By Catherine Shaffer
Staff Writer

Monday, April 2, 2012
The Genentech Inc. unit of Roche AG announced that its Phase III (EMILIA) trial of Immunogen Inc.-partnered asset trastuzumab emtansine (T-DM1) showed positive results. Patients randomized to treatment with T-DM1 had a significantly longer duration of progression-free survival than those receiving the control therapy, lapatinib plus capecitabine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription